Skip to main content

Table 3 Serum E2 levels and maximal ovarian diameter (MOD) of studied patients estimated throughout the observation period in both groups

From: Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study

 

Serum E2 level (pg/ml)

Maximal ovarian diameter (mm)

Control

Study

P value

Control

Study

P value

Day-0

5004 ± 792

4761 ± 940

>0.05

10.4 ± 5.8

9.4 ± 4.5

>0.05

Day-1

4212 ± 950a

3397 ± 1361a

0.021

10.2 ± 5.6

9.3 ± 4.6

>0.05

Day-2

3620 ± 1037a

2772 ± 1456a

0.011

9.6 ± 4.6

9.1 ± 4.2

>0.05

Day-3

3592 ± 862a

2067 ± 900a

0.005

9.4 ± 4.9

8.7 ± 4.3

>0.05

Day-4

2570 ± 914a

1452 ± 617a

0.007

9.2 ± 4.7

8.5 ± 4.3

>0.05

Day-5

1914 ± 965a

1173 ± 180a

0.003

9 ± 4.6

7.8 ± 4

>0.05

Day-6

1544 ± 812a

1173 ± 180a

0.006

8.5 ± 4.6

7.5 ± 4.2

>0.05

Day-7

1275 ± 588a

969 ± 118a

0.001

8.2 ± 4.5

7.3 ± 4

>0.05

Day-8

1044 ± 200a

902 ± 66a

0.001

7.9 ± 4.2

7.1 ± 3.7

>0.05

  1. Data are presented as mean (±SD); Day-0: time of enrolment; a: significant difference versus respective Day-0 data; P value for the difference between both groups